BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsou PS, Sawalha AH. Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases. FASEB J 2020;34:8810-23. [PMID: 32445534 DOI: 10.1096/fj.202000651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lazaratos AM, Annis MG, Siegel PM. GPNMB: a potent inducer of immunosuppression in cancer. Oncogene 2022. [PMID: 36050467 DOI: 10.1038/s41388-022-02443-2] [Reference Citation Analysis]
2 Shi Y, Shu J, Ning Z, Fan D, Shu H, Zhao H, Li L, Zhao N, Lu C, Lu A, He X. Analysis of Hepatic Lipid Metabolism and Immune Function During the Development of Collagen-Induced Arthritis. Front Immunol 2022;13:901697. [DOI: 10.3389/fimmu.2022.901697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Palisoc PJ, Vaikutis L, Gurrea-Rubio M, Model EN, O'mara MM, Ory S, Vichaikul S, Khanna D, Tsou PS, Sawalha AH. Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis. Front Immunol 2022;13:814533. [PMID: 35280996 DOI: 10.3389/fimmu.2022.814533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cherian P, Al-Khairi I, Jamal M, Al-Sabah S, Ali H, Dsouza C, Alshawaf E, Al-Ali W, Al-Khaledi G, Al-Mulla F, Abu-Farha M, Abubaker J. Association Between Factors Involved in Bone Remodeling (Osteoactivin and OPG) With Plasma Levels of Irisin and Meteorin-Like Protein in People With T2D and Obesity. Front Endocrinol (Lausanne) 2021;12:752892. [PMID: 34777249 DOI: 10.3389/fendo.2021.752892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Qin W, Wang H, Zhong W, Bai J, Qiao J, Lin Z. Amyloidosis cutis dyschromica cases caused by GPNMB mutations with different inheritance patterns. J Dermatol Sci 2021;104:48-54. [PMID: 34551863 DOI: 10.1016/j.jdermsci.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Han MM, Yuan XR, Shi X, Zhu XY, Su Y, Xiong DK, Zhang XM, Zhou H, Wang JN. The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Front Pharmacol 2021;12:732790. [PMID: 34539413 DOI: 10.3389/fphar.2021.732790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
7 Fisher JE Jr. Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates. Antibodies (Basel) 2021;10:15. [PMID: 33921632 DOI: 10.3390/antib10020015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang M, Modeste E, Dammer E, Merino P, Taylor G, Duong DM, Deng Q, Holler CJ, Gearing M, Dickson D, Seyfried NT, Kukar T. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathol Commun 2020;8:163. [PMID: 33028409 DOI: 10.1186/s40478-020-01037-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]